Using global statistical tests in long‐term Parkinson's disease clinical trials
Identifieur interne : 000916 ( Main/Exploration ); précédent : 000915; suivant : 000917Using global statistical tests in long‐term Parkinson's disease clinical trials
Auteurs : Peng Huang [États-Unis] ; Christopher G. Goetz [États-Unis] ; Robert F. Woolson [États-Unis] ; Barbara Tilley [États-Unis] ; Douglas Kerr [États-Unis] ; Yuko Palesch [États-Unis] ; Jordan Elm [États-Unis] ; Bernard Ravina [États-Unis] ; Kenneth J. Bergmann [États-Unis] ; Karl Kieburtz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-09-15.
English descriptors
- KwdEn :
Abstract
Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the long‐term decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed significant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22645
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Using global statistical tests in long‐term Parkinson's disease clinical trials</title><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name></author><author><name sortKey="Woolson, Robert F" sort="Woolson, Robert F" uniqKey="Woolson R" first="Robert F." last="Woolson">Robert F. Woolson</name></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name></author><author><name sortKey="Kerr, Douglas" sort="Kerr, Douglas" uniqKey="Kerr D" first="Douglas" last="Kerr">Douglas Kerr</name></author><author><name sortKey="Palesch, Yuko" sort="Palesch, Yuko" uniqKey="Palesch Y" first="Yuko" last="Palesch">Yuko Palesch</name></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name></author><author><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:18E069528157DF39F4838E56F149062782877FCC</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22645</idno><idno type="url">https://api.istex.fr/document/18E069528157DF39F4838E56F149062782877FCC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002047</idno><idno type="wicri:Area/Main/Curation">001D47</idno><idno type="wicri:Area/Main/Exploration">000916</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Using global statistical tests in long‐term Parkinson's disease clinical trials</title><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Oncology Biostatistics, Johns Hopkins University, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Woolson, Robert F" sort="Woolson, Robert F" uniqKey="Woolson R" first="Robert F." last="Woolson">Robert F. Woolson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Kerr, Douglas" sort="Kerr, Douglas" uniqKey="Kerr D" first="Douglas" last="Kerr">Douglas Kerr</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Oncology Biostatistics, Johns Hopkins University, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Palesch, Yuko" sort="Palesch, Yuko" uniqKey="Palesch Y" first="Yuko" last="Palesch">Yuko Palesch</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>U.S. Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-09-15">2009-09-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1732">1732</biblScope><biblScope unit="page" to="1739">1739</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">18E069528157DF39F4838E56F149062782877FCC</idno><idno type="DOI">10.1002/mds.22645</idno><idno type="ArticleID">MDS22645</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>global treatment effect</term><term>multiple outcomes</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the long‐term decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed significant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Sud</li><li>Illinois</li><li>Maryland</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name></region><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><name sortKey="Kerr, Douglas" sort="Kerr, Douglas" uniqKey="Kerr D" first="Douglas" last="Kerr">Douglas Kerr</name><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><name sortKey="Palesch, Yuko" sort="Palesch, Yuko" uniqKey="Palesch Y" first="Yuko" last="Palesch">Yuko Palesch</name><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><name sortKey="Woolson, Robert F" sort="Woolson, Robert F" uniqKey="Woolson R" first="Robert F." last="Woolson">Robert F. Woolson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000916 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000916 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:18E069528157DF39F4838E56F149062782877FCC
|texte= Using global statistical tests in long‐term Parkinson's disease clinical trials
}}
| This area was generated with Dilib version V0.6.23. |  |